Cancer vaccines represent a promising therapeutic approach in PC, designed to elicit robust tumor-specific CD4+ and CTL responses via recognition of tumor cells (non-antigen-specific) or TAAs (antigen-specific)[205,206]. This evidence concerns the gene CD4 and neoplasm.